Drugs For Obstructive Airway Diseases Table 188: Summary of changes in annual trends from pre ICDP to post ICDP period, medicines from the ATC2 class of 'Drugs for Obstructive Airway Diseases', by EverCtG status, age group and indicator. Age Group Indicator EverCtG NeverCtG 0 to 14 Patients dispensed Post ICDP increase No change in trend at least one script +8.0% to +15.9% Average scripts per Post ICDP increase No change in trend patient 0.0% to +2.5% 15 to 54 Patients dispensed Post ICDP increase No change in trend at least one script +7.9% to +15.9% Average scripts per Post ICDP increase Post ICDP positive levelling patient 0.0% to +3.2% -1.5% to 0.0% 55+ Patients dispensed No change in trend No change in trend at least one script Average scripts per No change in trend Post ICDP positive levelling patient -1.0% to 0.0% Source: KPMG. * Includes only medicines in this ATC2 class. Figure 142: Index of number of EverCtG patients that received at least one PBS script, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia (January to June 2010 = 100. * Includes only medicines in this ATC2 class. Figure 143 Index of number of NeverCtG patients that received at least one PBS script, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia (January to June 2010 = 100. * Includes only medicines in this ATC2 class. Figure 144: Number of PBS scripts dispensed per EverCtG patient, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia. * Includes only medicines in this ATC2 class. Figure 145 Number of PBS scripts dispensed per NeverCtG patient, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia.
Drugs For Obstructive Airway Diseases Table 188: Summary of changes in annual trends from pre ICDP to post ICDP period, medicines from the ATC2 class of 'Drugs for Obstructive Airway Diseases', by EverCtG status, age group and indicator. Age Group Indicator EverCtG NeverCtG 0 to 14 Patients dispensed at least one script Post ICDP increase +8.0% to +15.9% No change in trend Average scripts per patient Post ICDP increase 0.0% to +2.5% No change in trend 15 to 54 Patients dispensed at least one script Post ICDP increase +7.9% to +15.9% No change in trend Average scripts per patient Post ICDP increase 0.0% to +3.2% Post ICDP positive levelling -1.5% to 0.0% 55+ Patients dispensed at least one script No change in trend No change in trend Average scripts per patient No change in trend Post ICDP positive levelling -1.0% to 0.0% Source: KPMG. * Includes only medicines in this ATC2 class. Figure 142: Index of number of EverCtG patients that received at least one PBS script, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia (January to June 2010 = 100. * Includes only medicines in this ATC2 class. Figure 143 Index of number of NeverCtG patients that received at least one PBS script, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia (January to June 2010 = 100. * Includes only medicines in this ATC2 class. Figure 144: Number of PBS scripts dispensed per EverCtG patient, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia. * Includes only medicines in this ATC2 class. Figure 145 Number of PBS scripts dispensed per NeverCtG patient, Drugs for Obstructive Airway Diseases*, by age and six month period, Australia.
ICDP_appendices_vol4.docx